Dr. Reddy's forced to stop Suboxone generic rollout amid patent dispute by Eric Sagonowsky Monday, June 18, 2018 Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold.
Endo settles 1,300 testosterone liability lawsuits by Eric Sagonowsky Tuesday, June 12, 2018 Endo moved to resolve "all known" testosterone drug lawsuits it faced. The company last year set aside $200 million for the litigation.
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report by Eric Sagonowsky Monday, May 7, 2018 India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.
AndroGel trial do-over slashes AbbVie damages to $3M by Eric Sagonowsky Tuesday, March 27, 2018 AbbVie scored a major reduction of damages in a retrial of an AndroGel liability case brought by plaintiff Jesse Mitchell.
Endo, Teva agree to $270M Lidoderm pay-for-delay settlement by Eric Sagonowsky Thursday, March 22, 2018 Endo, Teva and a Japanese drugmaker have agreed to fork over more than $270 million to resolve a class-action suit over Lidoderm.
Judge puts drugmakers on course for first opioid trials by Eric Sagonowsky Thursday, March 8, 2018 Drugmakers haven't been able to reach a settlement with the cities and counties suing them over the opioid epidemic.
Mallinckrodt gets new subpoena in growing opioid crisis by Eric Sagonowsky Wednesday, February 28, 2018 As opioid scrutiny intensifies around the country, Mallinckrodt has received another subpoena seeking info about its sales of the powerful painkillers.
DOJ steps in to back opioid lawsuits by cities, counties by Eric Sagonowsky Wednesday, February 28, 2018 Hundreds of cities and counties have sued to hold opioid makers accountable for the addiction epidemic. Now the feds are getting involved.
Endo, GSK close to settling testosterone liability cases by Eric Sagonowsky Tuesday, February 27, 2018 The court overseeing testosterone lawsuits has stayed all proceedings relating to Endo and GSK so the companies can work to settle their cases.
Most opioid makers ditched promos long before Purdue by Beth Snyder Bulik Wednesday, February 14, 2018 Purdue made a splash with its plans to stop marketing opioids this week, but Endo, Teva, Allergan and J&J had already quit.
